CEL-SCI Says Teva Begins Multikine Phase III Study in Israel

CEL-SCI Corp. said that its partner, Teva Pharmaceutical Industries Ltd., has concluded the site initiation visit for the first Israeli clinical center in CEL-SCI's Phase III clinical trial for Multikine, the company’s flagship cancer immunotherapy.
RTT News